Prospective characterization of children positive for anti-MOG antibodies meeting Multiple Sclerosis diagnostic criteria (P4.6-042)

Objective: To characterize the clinical features and outcome of children meeting diagnostic criteria for multiple sclerosis (MS) who were seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOGabs). Background: A minority of subjects meeting the MS diagnostic criteria are MOGabs seropositive (MOG+). Whether these patients exhibit clinical features distinct from typical MS is unclear. Design/Methods: We assessed the presence of MOGabs in 66 children (median [IQR] age at onset 13.97 [IQR 10.88–15.06] years) diagnosed with MS according to 2010 international diagnostic criteria. Clinical, serological and imaging features were prospectively assessed for a median of 7 years from presentation, and compared between MOG+ and MOG− children using descriptive statistics. Results: At clinical onset, 11/66 (17%) children were MOG+. Seropositive patients were younger (p Conclusions: While meeting MS diagnostic criteria, children seropositive for MOGabs exhibit clinical and MRI features distinguishing them from MOG-negative typical relapsing MS patients. Disclosure: Dr. Fadda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Atara Biotherapeutics INC. Dr. Waters has nothing to disclose. Dr. Woodhall has nothing to disclose. Dr. Irani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with MedImmune and ADCT. Dr. Irani has received royalty, license fees, or contractual rights payments from LGI1, CASPR2 and contactin-2, licenced to Euroimmun Ltd. He receives royalties from the patent. Dr. Irani has received research support from UCB Pharma and ONO for immunology research. Dr. Brown has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen IDEC, NeuroRX. Dr. O’Mahony has nothing to disclose. Dr. Castro has nothing to disclose. Dr. Longoni has nothing to disclose. Dr. Yeh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Teva, Juno Therapeutics, ACI. Dr. Yeh has received research support from OIRM, MSSC/MSSF, NMSS, SickKids Foundation, CBMH, Guthy Jackson Foundation, CHAK, CMSC, SCN. Dr. Marrie has nothing to disclose. Dr. Arnold has nothing to disclose. Dr. Banwell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Bar-Or has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Atara Biotherapeutics, Biogen, Celgene/Receptos, Genentech/Roche, GlaxoSmithKline, Medimmune, Merck/EMD Serono, Novartis, Sanofi-Genzyme. Dr. Bar-Or has received research support from Atara Biotherapeutics, Biogen, Celgene/Receptos, Genentech/Roche, GlaxoSmithKline, Medimmune, Merck/EMD Serono, Novartis, Sanofi-Genzyme.